References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66(1):7-30; PMID:26742998; https://doi.org/10.3322/caac.21332
- Loeb S, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R. Overdiagnosis and overtreatment of prostate cancer. Eur Urol 2014; 65(6):1046-55; PMID:24439788; https://doi.org/10.1016/j.eururo.2013.12.062
- Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, Graff RE, Holst K, Möller S, Unger RH, et al. Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. JAMA 2016; 315(1):68-76; PMID:26746459; https://doi.org/10.1001/jama.2015.17703
- Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015; 161(5):1215-28; PMID:26000489; https://doi.org/10.1016/j.cell.2015.05.001
- Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med 2016; 375(5):443-53; PMID:27433846; https://doi.org/10.1056/NEJMoa1603144
- Schrader KA, Cheng DT, Joseph V, Prasad M, Walsh M, Zehir A, Ni A, Thomas T, Benayed R, Ashraf A, et al. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncol 2016; 2(1):104-11; PMID:26556299; https://doi.org/10.1001/jamaoncol.2015.5208
- Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366(10):883-92; PMID:22397650; https://doi.org/10.1056/NEJMoa1113205
- Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T, et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med 2016; 22(4):369-78; PMID:26928463; https://doi.org/10.1038/nm.4053
- Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. European Urology 2016; 69(6):992-5; PMID:26724258; https://doi.org/10.1016/j.eururo.2015.11.022
- Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015; 373(18):1697-708; PMID:26510020; https://doi.org/10.1056/NEJMoa1506859